Gossamer Bio
Sophia Kuo, PhD has a diverse work experience in the field of medical writing and scientific research. Sophia currently holds the position of Director, Medical Writing at Gossamer Bio since September 2022, where they manage the medical writing team and contributes to various projects. Prior to this, Sophia worked as a Principal Medical Writer at Gossamer Bio from March 2020 to September 2022. Before joining Gossamer Bio, they were a Senior Manager, Medical Writing at the same company from October 2018 to March 2020.
Before their time at Gossamer Bio, Sophia gained valuable experience at Penumbra Inc. Sophia joined the company as a Medical Writer, Clinical Affairs in October 2011 and served in various roles, including Senior Medical Writer and Project Manager, Medical Writing, Clinical Affairs. Sophia played a vital role in building collaborative cross-functional relationships and expanding the Medical Writing team at Penumbra Inc.
Sophia also worked as a Medical Writing Consultant at Pathway Therapeutics Ltd for a brief period in 2011, where they provided their expertise in medical writing.
Earlier in their career, Sophia served as a Senior Scientist at Exelixis from 2006 to 2010. In this role, they led projects related to drug discovery validation and optimization, including preclinical studies and plasma biomarker analysis. Sophia also gained experience in writing IND and NDA sections.
Overall, Sophia Kuo, PhD has a strong background in medical writing and scientific research, with significant experience in leading teams, building relationships, and contributing to drug development projects.
Sophia Kuo, PhD holds a Doctor of Philosophy (PhD) degree in Cancer Biology from Stanford University School of Medicine. Following their doctoral studies, they pursued a postdoctoral fellowship at Genentech, specializing in the fields of Angiogenesis and Neuroscience.
Gossamer Bio
1 followers
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.